New research by Wang in Alzheimer’s & Dementia suggests that semaglutide (Ozempic and Wegovy), a GLP-1 used for type 2 diabetes and weight loss, may reduce the risk of developing Alzheimer’s disease.
Findings include a 40%-70% lower Alzheimer’s risk among patients with type 2 diabetes taking semaglutide compared to other antidiabetic drugs. I continue to be fascinated with the emerging research on GLP-1s (such as my recent post on GLP-1s helping people with opioid use disorder).
Will GLP-1s be this decade's wonder drug?
Comments